These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

763 related items for PubMed ID: 24192217

  • 1. The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy.
    Wattjes MP, Richert ND, Killestein J, de Vos M, Sanchez E, Snaebjornsson P, Cadavid D, Barkhof F.
    Mult Scler; 2013 Dec; 19(14):1826-40. PubMed ID: 24192217
    [Abstract] [Full Text] [Related]

  • 2. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy.
    Yousry TA, Pelletier D, Cadavid D, Gass A, Richert ND, Radue EW, Filippi M.
    Ann Neurol; 2012 Nov; 72(5):779-87. PubMed ID: 23280794
    [Abstract] [Full Text] [Related]

  • 3. Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab.
    Kleinschmidt-DeMasters BK, Miravalle A, Schowinsky J, Corboy J, Vollmer T.
    J Neuropathol Exp Neurol; 2012 Jul; 71(7):604-17. PubMed ID: 22710964
    [Abstract] [Full Text] [Related]

  • 4. Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI.
    Wattjes MP, Barkhof F.
    Curr Opin Neurol; 2014 Jun; 27(3):260-70. PubMed ID: 24739400
    [Abstract] [Full Text] [Related]

  • 5. Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy.
    Metz I, Radue EW, Oterino A, Kümpfel T, Wiendl H, Schippling S, Kuhle J, Sahraian MA, Gray F, Jakl V, Häusler D, Brück W.
    Acta Neuropathol; 2012 Feb; 123(2):235-45. PubMed ID: 22057786
    [Abstract] [Full Text] [Related]

  • 6. Review of progressive multifocal leukoencephalopathy and natalizumab.
    Aksamit AJ.
    Neurologist; 2006 Nov; 12(6):293-8. PubMed ID: 17122725
    [Abstract] [Full Text] [Related]

  • 7. Presumptive progressive multifocal leukoencephalopathy in multiple sclerosis after natalizumab therapy.
    Eisele P, Szabo K, Hornberger E, Griebe M, Hennerici MG, Kieseier BC, Gass A.
    J Neuroimaging; 2014 Nov; 24(4):425-8. PubMed ID: 23323645
    [Abstract] [Full Text] [Related]

  • 8. Atypical MRI features at early onset natalizumab-associated progressive multifocal leukoencephalopathy: a case report.
    Piola M, Di Palma F, Mascoli N, Binda S, Arnaboldi M, Rezzonico M.
    J Neurol Sci; 2014 May 15; 340(1-2):213-4. PubMed ID: 24642511
    [Abstract] [Full Text] [Related]

  • 9. MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS.
    Wattjes MP, Wijburg MT, Vennegoor A, Witte BI, de Vos M, Richert ND, Uitdehaag BM, Barkhof F, Killestein J, Dutch-Belgian Natalizumab-associated PML study group.
    J Neurol Neurosurg Psychiatry; 2016 Aug 15; 87(8):879-84. PubMed ID: 26369555
    [Abstract] [Full Text] [Related]

  • 10. Inflammatory natalizumab-associated PML: baseline characteristics, lesion evolution and relation with PML-IRIS.
    Wattjes MP, Wijburg MT, van Eijk J, Frequin S, Uitdehaag BMJ, Barkhof F, Warnke C, Killestein J, Dutch-Belgian Natalizumab-Associated PML Study Group.
    J Neurol Neurosurg Psychiatry; 2018 May 15; 89(5):535-541. PubMed ID: 29142146
    [Abstract] [Full Text] [Related]

  • 11. Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab.
    Blinkenberg M, Sellebjerg F, Leffers AM, Madsen CG, Sørensen PS.
    Mult Scler; 2013 Aug 15; 19(9):1226-9. PubMed ID: 23508652
    [Abstract] [Full Text] [Related]

  • 12. MRI pattern in asymptomatic natalizumab-associated PML.
    Wattjes MP, Vennegoor A, Steenwijk MD, de Vos M, Killestein J, van Oosten BW, Mostert J, Siepman DA, Moll W, van Golde AE, Frequin ST, Richert ND, Barkhof F.
    J Neurol Neurosurg Psychiatry; 2015 Jul 15; 86(7):793-8. PubMed ID: 25205744
    [Abstract] [Full Text] [Related]

  • 13. Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases.
    N'gbo N'gbo Ikazabo R, Mostosi C, Quivron B, Delberghe X, El Hafsi K, Lysandropoulos AP.
    Clin Ther; 2016 Mar 15; 38(3):670-5. PubMed ID: 26856928
    [Abstract] [Full Text] [Related]

  • 14. Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients.
    Wattjes MP, Wijburg MT, Vennegoor A, Witte BI, Roosendaal SD, Sanchez E, Liu Y, Martins Jarnalo CO, Richert ND, Uitdehaag BM, Barkhof F, Killestein J.
    Mult Scler; 2016 Aug 15; 22(9):1174-83. PubMed ID: 26564995
    [Abstract] [Full Text] [Related]

  • 15. Diagnosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place?
    Wattjes MP, Vennegoor A, Mostert J, van Oosten BW, Barkhof F, Killestein J.
    J Neurol; 2014 Jun 15; 261(6):1139-43. PubMed ID: 24705790
    [Abstract] [Full Text] [Related]

  • 16. Multiple sclerosis update: use of MRI for early diagnosis, disease monitoring and assessment of treatment related complications.
    Igra MS, Paling D, Wattjes MP, Connolly DJA, Hoggard N.
    Br J Radiol; 2017 Jun 15; 90(1074):20160721. PubMed ID: 28362522
    [Abstract] [Full Text] [Related]

  • 17. Progressive multifocal leukoencephalopathy: a review of the neuroimaging features and differential diagnosis.
    Sahraian MA, Radue EW, Eshaghi A, Besliu S, Minagar A.
    Eur J Neurol; 2012 Aug 15; 19(8):1060-9. PubMed ID: 22136455
    [Abstract] [Full Text] [Related]

  • 18. [A case of subtentorial progressive multifocal leucoencephalopathy in a patient treated with natalizumab].
    Simaniv TO, Ivanova MV, Bryukhov VV, Zakharova MN.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2019 Aug 15; 119(2. Vyp. 2):98-106. PubMed ID: 31156248
    [Abstract] [Full Text] [Related]

  • 19. Magnetic resonance imaging changes following natalizumab discontinuation in multiple sclerosis patients with progressive multifocal leukoencephalopathy.
    Hodel J, Bapst B, Outteryck O, Verclytte S, Deramecourt V, Benadjaoud MA, Pruvo JP, Vermersch P, Leclerc X.
    Mult Scler; 2018 Dec 15; 24(14):1902-1908. PubMed ID: 29343163
    [Abstract] [Full Text] [Related]

  • 20. Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS.
    Gheuens S, Smith DR, Wang X, Alsop DC, Lenkinski RE, Koralnik IJ.
    Neurology; 2012 May 01; 78(18):1390-3. PubMed ID: 22517104
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.